HKEX Stock Code: 01093
English
|
繁體
|
简体
Home
About Us
Products
News
Competence
Investor Relations
Contact Us
Corporate Profile
Corporate Information
Corporate Culture
Board of Directors
Corporate Governance
Products Overview
Finished Drugs
Bulk Drugs
Press Releases
Strategies
Quality
Research and Development
IR Overview
Financial Reports
CSR Reports
Announcements & Notices
Returns on Share Capital
Circulars
Presentations
Documents on Display
Shareholder Services
Notice(s) of Replacement
of Lost Share Certificates
Financial Calendar
Financial Summary
IR Contacts
Investor Relations
IR Overview
Financial Reports
CSR Reports
Announcements & Notices
Returns on Share Capital
Circulars
Presentations
Documents on Display
Shareholder Services
Notice(s) of Replacement of Lost Share Certificates
Financial Calendar
Financial Summary
IR Contacts
Home
>
Investor Relations
> Announcements & Notices
Announcements & Notices
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
Jan
30
VOLUNTARY ANNOUNCEMENT - ENTERING INTO A STRATEGIC COLLABORATION AND LICENSE AGREEMENT WITH ASTRAZENECA FOR THE DEVELOPMENT OF INNOVATIVE LONG-ACTING PEPTIDE MEDICINES
Jan
29
VOLUNTARY ANNOUNCEMENT - SYS6055 INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Jan
23
VOLUNTARY ANNOUNCEMENT - GRANT OF AWARDED SHARES PURSUANT TO THE SHARE AWARD SCHEME OF THE COMPANY
Jan
15
INDICATIVE RESULTS OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2025
Jan
13
VOLUNTARY ANNOUNCEMENT - POTENT ALDOSTERONE SYNTHASE INHIBITOR (SYH2072 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Jan
12
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTS MARKETING AUTHORISATION APPLICATION FOR PRUSOGLIPTIN AND METFORMIN EXTENDED-RELEASE TABLETS
Jan
02
VOLUNTARY ANNOUNCEMENT - NINTEDANIB ESILATE POWDER FOR INHALATION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Please download the latest "
Acrobat Reader
" to view the PDF.
